

Franz Waibel



---

## BIOGRAPHY

Franz Waibel, PhD, MBA has over 25 years of experience in the field of HTA and value assessment of medicines and medical products. Following a career in the pharmaceutical industry he works now as a consultant in the field of HTA, access to healthcare and related policy matters. He provides his services as an independent consultant, based in Zug, Switzerland, and in addition as an Associated Partner with Executive Insight Healthcare Consultants, Zürich and London.

He is especially interested in improving patient access to scientific medical innovations and the alignment of key stakeholders throughout the product lifecycle for the benefit of the patient.

Throughout his career, he has led and initiated innovative strategic approaches for developing products with a focus on HTA and patient access which included early engagement initiatives with single or multiple stakeholders, development of managed entry agreements / risk sharing agreements and the development of integrated solutions offering economic savings for the healthcare system.

Franz is a member of HTAi since 2005 and has been serving for a number of years on the HTAi Global Policy Forum. He is a member of the HTAi Patient and Citizen Involvement IG and the HTAi Regulatory Interactions and Conditional Coverage IG.

During his corporate career his work spanned key fields related to HTA, namely science, policy, value assessment and patient access. After initial work as a scientist and entry roles in organizational development, business development and marketing, he subsequently led public & governmental affairs, patient advocacy, pricing, health economics, outcomes research, RWE and access organizations with global, regional and local responsibilities within Novartis (until 1999), Pfizer (2000-2006), Merck&Co (2007-2008), Bayer (2009-2013) and Vifor Pharma (2015-2018). He has worked in Switzerland, the USA, Belgium and Germany. He has been involved in healthcare system and HTA policy matters and has frequently engaged in scientific questions across many jurisdictions in Latin America, North America, Asia and Europe. He represented the industry in cross stakeholder initiatives at the EU level, for example at the EU High-level Pharmaceutical Forum, and served on various association working groups, think tanks (e.g. CIRIS) and boards (EuropaBio). He has worked on a broad range of therapeutic areas, including oncology, cardiovascular, renal and rare diseases.

Through his longstanding leadership experience and strong business acumen, he has a strong track record in establishing organizational efficiency and effectiveness, leading through transformational change, furthering talent and competence development and providing strategic as well as operational guidance.

Franz studied Cell Biology, Genetics, and Pharmacology at the University of Freiburg, Germany, he holds a PhD in Cell Biology from the University of Basel, Switzerland, and an MBA from the University of Birmingham, UK. In addition, he has attended numerous post-graduate trainings, as e.g. in pharmaco-economics, HTA and negotiation training. He is a certified coach and mediator and holds Swiss and German citizenships.

---

## VISION STATEMENT

In line with the current strategic plan of HTAi, I will support the society to maintain and further strengthen its position as the leading global discussion platform for all stakeholders engaged in the efficient production and use of HTAs in decision making.

In the fast evolving and changing environment for HTA, I specifically intend to focus on the following areas:

- New emerging technologies, as for example gene therapy and targeted therapies in oncology and immunotherapy, in combination with the emergence of big data and more sophisticated analytics will require continued advancement of approaches in HTA. A key success factor will be the increased collaboration among stakeholders in order to improve the efficiency of developing the technologies with the appropriate evidence allowing for HTA. I aim to contribute to the definition and design of *advanced approaches for multi-stakeholder collaboration, engagement and partnering* with the ultimate goal to overcome challenges arising from new technologies.
- A key to the continued evolution of HTA capacity building across countries and specifically in emerging HTA countries, will be the further refinement of HTA competences, HTA capacity and HTA talent development. I will support the development of an *integrated strategy for talent, competence and capacity development* across countries. This will enable on one hand cohesion and common practices across the HTAi community and secure on the other hand the early identification and support for future talent and leadership within the HTA community at local and global level.
- Focusing resources on the key strategic issues facing HTAi and the HTA community will be essential to the success and impact of the society and HTA decision makers. I will strive to further advance the *strategic plan beyond 2020* and support an inclusive process for the refinement of strategic priorities, an update for the strategic plan and the establishment of key performance indicators and targets.

These activities in combination with other efforts as defined in the HTAi areas of focus, will help the HTA community to advance HTA and continue to position HTAi as the leading global discussion platform for all stakeholders engaged in the production and use of HTA decision making.